What it’s good to know:

– Labcorp (NYSE: LH), a world chief in progressive and complete laboratory companies, in the present day introduced an expanded collaboration with Ultima Genomics to make the most of its UG 100TM sequencing resolution and ppmSeqTM know-how to discover novel scientific functions for complete genome sequencing (WGS), together with molecular residual illness (MRD) in sufferers with early-stage strong tumors.

– Labcorp just lately launched Labcorp® Plasma Detect™, the primary clinically validated, tumor-informed, WGS-based circulating tumor DNA (ctDNA) MRD resolution for analysis and experimental use. Labcorp plans to make the most of Ultima’s UG 100 platform and ppmSeq know-how, which, mixed with Plasma Detect, have demonstrated in preliminary information the power to detect uncommon variants at extraordinarily low cutoffs, improved sensitivity and specificity, and extra environment friendly, scalable and cost-effective workflows.

Labcorp Enhances Entire Genome Sequencing Capabilities By means of Expanded Collaboration with Ultima Genomics

Labcorp (NYSE: LH) is a world chief in progressive and complete laboratory companies, serving to physicians, hospitals, pharmaceutical firms, researchers and sufferers clarify and assured choices. By means of unmatched diagnostics and drug discovery laboratory capabilities, Labcorp offers insights and advances science to enhance well being and enhance lives.

“By combining Labcorp’s management, testing capabilities and intensive community with the accuracy, scalability and cost-effectiveness of Ultima’s know-how, we may help rework oncology testing for pathologists, oncologists and our biopharmaceutical companions,” mentioned Shakti Ramkissoon, MD, PhD, MBA, vice chairman, medical chief for oncology at Labcorp. “By means of this collaboration, Labcorp goals to realize higher effectivity, scalability and cost-effectiveness whereas enhancing entry to reasonably priced genetic testing in rising areas with vital unmet want.”